{"id":"https://openalex.org/W2016229228","doi":"https://doi.org/10.1016/j.pupt.2007.12.003","title":"Denufosol: A review of studies with inhaled P2Y2 agonists that led to Phase 3","display_name":"Denufosol: A review of studies with inhaled P2Y2 agonists that led to Phase 3","publication_year":2008,"publication_date":"2008-01-02","ids":{"openalex":"https://openalex.org/W2016229228","doi":"https://doi.org/10.1016/j.pupt.2007.12.003","mag":"2016229228","pmid":"https://pubmed.ncbi.nlm.nih.gov/18276176"},"language":"en","primary_location":{"id":"doi:10.1016/j.pupt.2007.12.003","doi":"https://doi.org/10.1016/j.pupt.2007.12.003","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.pupt.2007.12.003","pdf_url":null,"source":{"id":"https://openalex.org/S102131606","display_name":"Pulmonary Pharmacology & Therapeutics","issn_l":"1094-5539","issn":["1094-5539","1522-9629"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pulmonary Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107277988","display_name":"Donald J. Kellerman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Donald Kellerman","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA. DKellerman@inspirepharm.com","Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA. DKellerman@inspirepharm.com","institution_ids":[]},{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079443276","display_name":"Andrea R. Mospan","orcid":"https://orcid.org/0000-0002-3419-8276","observed_orcids":["https://orcid.org/0000-0002-3419-8276"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea Rossi Mospan","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032437529","display_name":"Jean Engels","orcid":"https://orcid.org/0009-0008-0098-5133","observed_orcids":["https://orcid.org/0009-0008-0098-5133"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jean Engels","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053093524","display_name":"Amy E. Schaberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy Schaberg","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079543650","display_name":"JoAnn C. Gorden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JoAnn Gorden","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109964936","display_name":"Lynn Smiley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lynn Smiley","raw_affiliation_strings":["Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200, Durham, NC, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5107277988"],"corresponding_institution_ids":[],"apc_list":{"value":3730,"currency":"USD","value_usd":3730},"apc_paid":null,"fwci":2.5023,"has_fulltext":false,"cited_by_count":101,"citation_normalized_percentile":{"value":0.92248062,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"21","issue":"4","first_page":"600","last_page":"607"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.00430000014603138,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cystic-fibrosis","display_name":"cystic fibrosis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/mucociliary-clearance","display_name":"mucociliary clearance","score":0.7900000214576721},{"id":"https://openalex.org/keywords/nebulized-drug-delivery","display_name":"nebulized drug delivery","score":0.6880000233650208},{"id":"https://openalex.org/keywords/lung-deposition","display_name":"lung deposition","score":0.6269999742507935},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8899999856948853},{"id":"https://openalex.org/keywords/systemic-absorption","display_name":"systemic absorption","score":0.5509999990463257},{"id":"https://openalex.org/keywords/cough","display_name":"cough","score":0.42100000381469727},{"id":"https://openalex.org/keywords/fev1","display_name":"FEV1","score":0.8930000066757202},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.414000004529953}],"concepts":[{"id":"https://openalex.org/C114682108","wikidata":"https://www.wikidata.org/wiki/Q1952044","display_name":"Mucociliary clearance","level":3,"score":0.6675039529800415},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6155648231506348},{"id":"https://openalex.org/C2780352487","wikidata":"https://www.wikidata.org/wiki/Q2281580","display_name":"Nebulizer","level":2,"score":0.6038631796836853},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5950442552566528},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5528106093406677},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5384291410446167},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.508592963218689},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5039340853691101},{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.480426549911499},{"id":"https://openalex.org/C534529494","wikidata":"https://www.wikidata.org/wiki/Q7891","display_name":"Respiratory system","level":2,"score":0.43399083614349365},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3897179961204529},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37754830718040466},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.3763018846511841},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.22407037019729614},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1745859980583191},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000280","descriptor_name":"Administration, Inhalation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003550","descriptor_name":"Cystic Fibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003845","descriptor_name":"Deoxycytosine Nucleotides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003845","descriptor_name":"Deoxycytosine Nucleotides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003845","descriptor_name":"Deoxycytosine Nucleotides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005541","descriptor_name":"Forced Expiratory Volume","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011122","descriptor_name":"Polyphosphates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011122","descriptor_name":"Polyphosphates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014500","descriptor_name":"Uracil Nucleotides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014500","descriptor_name":"Uracil Nucleotides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014529","descriptor_name":"Uridine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014529","descriptor_name":"Uridine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014529","descriptor_name":"Uridine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014529","descriptor_name":"Uridine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058473","descriptor_name":"Receptors, Purinergic P2Y2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058910","descriptor_name":"Purinergic P2 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.pupt.2007.12.003","doi":"https://doi.org/10.1016/j.pupt.2007.12.003","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.pupt.2007.12.003","pdf_url":null,"source":{"id":"https://openalex.org/S102131606","display_name":"Pulmonary Pharmacology & Therapeutics","issn_l":"1094-5539","issn":["1094-5539","1522-9629"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pulmonary Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:18276176","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18276176","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pulmonary pharmacology & therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W6308305","https://openalex.org/W628370770","https://openalex.org/W992232202","https://openalex.org/W1999274391","https://openalex.org/W2005285859","https://openalex.org/W2055857822","https://openalex.org/W2070396410","https://openalex.org/W2076205950","https://openalex.org/W2077364716","https://openalex.org/W2083840551","https://openalex.org/W2087340871","https://openalex.org/W2096405956","https://openalex.org/W2101273248","https://openalex.org/W2103043501","https://openalex.org/W2104746568","https://openalex.org/W2136025669","https://openalex.org/W2144712242","https://openalex.org/W2157534655","https://openalex.org/W2171510247","https://openalex.org/W2333398204","https://openalex.org/W2338243080","https://openalex.org/W2411287349","https://openalex.org/W2488797195","https://openalex.org/W4236247973","https://openalex.org/W4243259101","https://openalex.org/W4250959143","https://openalex.org/W4285719527","https://openalex.org/W6714695823"],"related_works":["https://openalex.org/W2171510247","https://openalex.org/W2076739918","https://openalex.org/W2083840551","https://openalex.org/W2017586861","https://openalex.org/W2170130419","https://openalex.org/W2009104597","https://openalex.org/W1986035695","https://openalex.org/W2030586543","https://openalex.org/W2159671628","https://openalex.org/W2052819126"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}